Frances Broyles is an Endocrinology/Metabolic physician affiliated with Rainier Clinical Research Center. OpenAlex indexes 25 publications with 459 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
515 Minor Ave
Ste 300
Seattle, WA 981042120
Telephone
206-386-9500Registry record last updated 20 Jun 2008.
Clinical trials
- Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
Sponsor: Medtronic MiniMed, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year202522 payments
- Abbott LaboratoriesProgram year20251 payment
- Insulet CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
35%GLP-1 receptor agonist9.8%Ozempic45%Victoza 3-Pak30%Trulicity25%Part D<11 patientsInsulin Analog8.6%Lantus Solostar35%Novolog Flexpen22%Humalog Kwikpen U-10017%Novolog16%Basaglar Kwikpen U-10011%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
34.9%l-Thyroxine22.7%Levothyroxine Sodium90%Synthroid10%Part D≥79 patientsl-Triiodothyronine7.4%Liothyronine Sodium100%Part D≥28 patients+ 1 more class in this area
Cardiovascular
16%Statin8.8%Atorvastatin Calcium77%Rosuvastatin Calcium23%Part D<11 patientsThiazide diuretic1.9%Hydrochlorothiazide100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
New England Journal of Medicine
2025 - Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor
Diabetes Technology & Therapeutics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”